Multimodal nanoparticle-containing modified suberoylanilide hydroxamic acid polymer conjugates to mitigate immune dysfunction in severe inflammation.

"data s1."

"CONFLICT OF INTEREST STATEMENT The authors declare the following competing financial interest(s): Ryan M. Pearson, Steven Fletcher, and Nhu Truong are inventors on a patent application that describes SAHA‐OH and iNP‐SAHA technology."

"This research was supported by Startup funds from the University of Maryland School of Pharmacy, the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R35GM142752, the Shock Society Faculty Research Award awarded to Ryan M. Pearson, and the UMGCCC P30 grant under award P30CA134274 from the National Cancer Institute. Nhu Truong is supported by a PhRMA Foundation Pre‐doctoral Fellowship in Drug Delivery. Additional support was provided by the NIH/NIAID Signaling Pathways in Innate Immunity Training Program (NIH T32AI095190) and NIH/NHLBI Interdisciplinary Training Program in Cardiovascular Disease (NIH T32HL007698) to support Jackline Joy Martin Lasola. We would like to thank the University of Maryland School of Medicine's & Greenebaum Comprehensive Cancer Center's Flow Cytometry Core—Baltimore, Maryland. This publication was supported by funds through the Maryland Department of Health's Cigarette Restitution Fund Program and the National Cancer Institute—Cancer Center Support Grant (CCSG)—P30CA134274. We also thank Pathology Biorepository Shared Services Core (Baltimore, MD) for their assistance in tissue processing and BioRender for preparing graphics. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the Shock Society, or the PhRMA Foundation."